Brokerages Set Ventyx Biosciences, Inc. (NASDAQ:VTYX) PT at $15.50

Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) have been assigned an average rating of “Moderate Buy” from the five analysts that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $15.50.

Several research firms recently issued reports on VTYX. Wells Fargo & Company raised their price target on Ventyx Biosciences from $11.00 to $14.00 and gave the company an “overweight” rating in a report on Friday, November 7th. Oppenheimer upped their target price on shares of Ventyx Biosciences from $9.00 to $14.00 and gave the company an “outperform” rating in a research report on Monday, October 27th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Ventyx Biosciences in a research note on Wednesday, October 8th. Canaccord Genuity Group boosted their price target on shares of Ventyx Biosciences from $14.00 to $16.00 and gave the stock a “buy” rating in a research note on Friday, November 7th. Finally, HC Wainwright upgraded shares of Ventyx Biosciences from a “neutral” rating to a “buy” rating and set a $18.00 price objective on the stock in a report on Wednesday, November 5th.

Ventyx Biosciences Price Performance

VTYX stock opened at $9.03 on Friday. The company has a 50 day moving average price of $8.75 and a 200 day moving average price of $4.88. Ventyx Biosciences has a fifty-two week low of $0.78 and a fifty-two week high of $10.55. The stock has a market capitalization of $644.38 million, a PE ratio of -6.02 and a beta of 1.22.

Ventyx Biosciences (NASDAQ:VTYX) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.13. As a group, equities analysts expect that Ventyx Biosciences will post -2.09 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Raju Mohan sold 47,345 shares of the company’s stock in a transaction dated Thursday, December 18th. The stock was sold at an average price of $7.72, for a total value of $365,503.40. Following the completion of the sale, the chief executive officer owned 2,372,863 shares in the company, valued at approximately $18,318,502.36. This represents a 1.96% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider John Nuss sold 12,675 shares of the stock in a transaction dated Thursday, December 18th. The shares were sold at an average price of $7.72, for a total value of $97,851.00. Following the completion of the transaction, the insider directly owned 489,481 shares in the company, valued at $3,778,793.32. The trade was a 2.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 14.49% of the company’s stock.

Institutional Trading of Ventyx Biosciences

A number of institutional investors and hedge funds have recently modified their holdings of VTYX. Hudson Bay Capital Management LP bought a new position in Ventyx Biosciences during the 2nd quarter worth approximately $34,000. Persistent Asset Partners Ltd bought a new stake in Ventyx Biosciences in the third quarter valued at approximately $51,000. Pallas Capital Advisors LLC acquired a new stake in Ventyx Biosciences in the second quarter worth $38,000. Engineers Gate Manager LP bought a new position in shares of Ventyx Biosciences during the second quarter worth $42,000. Finally, Jacobs Levy Equity Management Inc. acquired a new position in shares of Ventyx Biosciences in the 3rd quarter valued at $61,000. 97.88% of the stock is owned by institutional investors.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome.